Canaan Partners X LLC's Q3 2020 13F: 1 position resized, no new positions or exits

Form 13F-HR for the quarter ended Sep 30, 2020 · filed Oct 26, 2020 · 3 reported positions · accession 0000950123-20-010459

What changed this quarter

Canaan Partners X LLC's changes in reported equity positions, Q3 2020
Activity Security Weight before Weight now Change Shares Shares %
Reduced NextCure Inc (NXTC) 52.2% 29.9% −22.2 pts −317K sh −16%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 100.0% of the equity book

No changes in the top 10 this quarter

# Security Weight before Weight now
1 IDEAYA Biosciences Inc (IDYA) 45.4% 66.4%
2 NextCure Inc (NXTC) 52.2% 29.9%
3 Iterum Therapeutics plc (ITRM) 2.5% 3.6%

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).